What is Quantum Surgical?
Founded in 2017, Quantum Surgical operates at the intersection of artificial intelligence and surgical robotics. The company is best known for its Epione platform, a sophisticated robotic-assisted system designed to facilitate minimally invasive tumor ablation. By providing interventional radiologists with high-precision tools, the company effectively standardizes complex cancer treatments, thereby enhancing patient outcomes and operational efficiency in clinical settings. Its market position is defined by a commitment to democratizing access to state-of-the-art cancer care, moving beyond traditional surgical limitations to offer more comfortable, effective, and scalable treatment options for patients globally.
How much funding has Quantum Surgical raised?
Quantum Surgical has raised a total of $68M across 1 funding round:
Private Equity
$68M
Private Equity (2025): $68M, investors not publicly disclosed
Key Investors in Quantum Surgical
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Quantum Surgical?
With this major strategic investment, Quantum Surgical is poised to enter a new phase of enterprise-level expansion. The capital will likely be deployed to scale manufacturing capabilities, broaden the clinical application of the Epione platform, and strengthen its regulatory footprint in international markets. As the company continues to build on its track record of successful patient treatments, the focus will shift toward long-term commercialization and the integration of next-generation AI features that further automate and refine tumor ablation procedures. This growth trajectory suggests a transition from a specialized innovator to a dominant player in the global medical technology sector, setting a new benchmark for robotic-assisted oncology.
See full Quantum Surgical company page
